Rochelle Bagatell Research Program
Led by Rochelle Bagatell, MD, researchers in the Bagatell Research Program are focused on clinically evaluating new targeted cancer treatments and immunotherapies to treat children with relapsed and refractory neuroblastomas. The long-term goal of the research is to develop new treatments for high-risk pediatric neuroblastomas that are more effective and less toxic than existing therapies.
Comparison of inpatient costs for children treated on the AAML0531 clinical trial: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2015 Oct;62(10):1775-81.
Getz KD, Li Y, Alonzo TA, Hall M, Gerbing RB, Sung L, Huang YS, Arnold S, Seif AE, Miller TP, Bagatell R, Fisher BT, Adamson PC, Gamis A, Keren R, Aplenc R.
Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2015 Jul;62(7):1184-9.
Miller TP, Troxel AB, Li Y, Huang Y-S, Alonzo TA, Gerbing RB, Hall M, Torp K, Fisher BT, Bagatell R, Seif AE, Sung L, Gamis A, Rubin D, Luger S, Aplenc R.
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2014 Oct;61(10):1792-7.
Norris RE, Shusterman S, Gore L, Muscal JA, Macy ME, Fox E, Berkowitz N, Buchbinder A, Bagatell R.